Daiichi Sankyo delayed its fiscal year ended March 31, 2026 earnings announcement from April 27 to May 11, 2026, due to additional time needed to finalize financial figures amid review of oncology supply plans and loss provisions for contract manufacturers.125
The company will release its 5-year business plan (FY2026-2030) on the same day, May 11, advanced from May 19.124
Shares fell approximately 10-11% on April 24, 2026, closing at around 2,497-2,505 yen, hitting a 4-year low.1347
The delay stems from rapidly changing business conditions affecting oncology products and development pipeline.125
This follows prior concerns, including a weak J.P. Morgan presentation and recent sale of OTC business to Suntory.14
Sources:
1. https://www.biospace.com/business/daiichi-sankyo-shares-slip-after-delaying-annual-earnings-report
2. https://www.marketscreener.com/news/daiichi-sankyo-announces-rescheduling-of-the-announcement-of-consolidated-financial-results-for-year-ce7f59dfd980f220
3. https://www.investing.com/news/stock-market-news/daiichi-sankyo-stock-tumbles-on-results-delay-provision-93CH-4634879
4. https://www.morningstar.com/news/dow-jones/20260424319/shares-of-japanese-drugmaker-daiichi-sankyo-tumble-on-delay-in-earnings
5. https://japanir.jp/en/company/company-4568/ir/4568-20260424-01wpdisclosure_update/
7. https://www.investing.com/news/stock-market-news/daiichi-sankyo-shares-slide-to-4yr-low-after-co-delays-annual-earnings-4634533